Omalizumab is commonly recommended for the treatment of severe refractory asthma. A special group of patients are pregnant women with asthma, for whom the risks of inadequately treated asthma must be weighed against the risks of biological treatment for the fetus. EXPECT is a pregnancy registry that has served since 2006 as a prospective observational study; its aim is to collect data on women treated with omalizumab during pregnancy and compare it with data from asthmatic women who did not receive omalizumab.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
